Incidence, mortality, and risk factors of acute kidney injury after immune checkpoint inhibitors: Systematic review and meta-analysis of real-world evidence
- 30 May 2023
- journal article
- review article
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 115, 88-95
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trialsCritical Reviews in Oncology/Hematology, 2017
- Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 studyThe Lancet Oncology, 2017
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced MelanomaJournal of Clinical Oncology, 2017
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort studyThe Lancet Oncology, 2017
- Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitorsKidney International, 2016
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialThe Lancet Oncology, 2015
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated MelanomaNew England Journal of Medicine, 2015
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008